Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Chao

Showing results (71-80 of 116) with videos related to

Pageof 12
Sort By:
The Oncologist|July 21, 2021
Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction AdenocarcinomaDaniel V Catenacci, Joseph Chao, Kei Muro, et al.
The Lancet. Oncology|June 17, 2023
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 studyEric Van Cutsem, Maria di Bartolomeo, Elizabeth Smyth, et al.
The Oncologist|December 21, 2019
A Pilot Feasibility Study of Yttrium-90 Liver Radioembolization Followed by Durvalumab and Tremelimumab in Patients with Microsatellite Stable Colorectal Cancer Liver MetastasesChongkai Wang, John Park, Ching Ouyang, et al.
JAMA Network Open|December 10, 2021
A Comparison of Clinicopathologic Outcomes Across Neoadjuvant and Adjuvant Treatment Modalities in Resectable Gastric CancerEric Anderson, Alexis LeVee, Sungjin Kim, et al.
World Journal of Gastrointestinal Oncology|March 23, 2022
Chemotherapy predictors and a time-dependent chemotherapy effect in metastatic esophageal cancerLauren Midthun, Sungjin Kim, Andrew Hendifar, et al.
Cancer Chemotherapy and Pharmacology|January 10, 2019
A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavityMihaela C Cristea, Paul Frankel, Timothy Synold, et al.
Journal for Immunotherapy of Cancer|February 5, 2024
Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cellsGregory P Botta, Joseph Chao, Hong Ma, et al.
World Journal of Gastrointestinal Surgery|October 7, 2020
Impact of palliative therapies in metastatic esophageal cancer patients not receiving chemotherapySungjin Kim, Timothy P DiPeri, Michelle Guan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2025
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory <i>KRAS</i> G12C Colorectal CancerFilippo Pietrantonio, Lisa Salvatore, Taito Esaki, et al.
Annals of Surgical Oncology|August 13, 2021
PIPAC for the Treatment of Gynecologic and Gastrointestinal Peritoneal Metastases: Technical and Logistic Considerations of a Phase 1 TrialMustafa Raoof, Gautam Malhotra, Adrian Kohut, et al.
Pageof 12

Showing results (71-80 of 116) with videos related to

Sort By:
Pageof 12
The Oncologist|July 21, 2021
Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction AdenocarcinomaDaniel V Catenacci, Joseph Chao, Kei Muro, et al.
The Lancet. Oncology|June 17, 2023
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 studyEric Van Cutsem, Maria di Bartolomeo, Elizabeth Smyth, et al.
The Oncologist|December 21, 2019
A Pilot Feasibility Study of Yttrium-90 Liver Radioembolization Followed by Durvalumab and Tremelimumab in Patients with Microsatellite Stable Colorectal Cancer Liver MetastasesChongkai Wang, John Park, Ching Ouyang, et al.
JAMA Network Open|December 10, 2021
A Comparison of Clinicopathologic Outcomes Across Neoadjuvant and Adjuvant Treatment Modalities in Resectable Gastric CancerEric Anderson, Alexis LeVee, Sungjin Kim, et al.
World Journal of Gastrointestinal Oncology|March 23, 2022
Chemotherapy predictors and a time-dependent chemotherapy effect in metastatic esophageal cancerLauren Midthun, Sungjin Kim, Andrew Hendifar, et al.
Cancer Chemotherapy and Pharmacology|January 10, 2019
A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavityMihaela C Cristea, Paul Frankel, Timothy Synold, et al.
Journal for Immunotherapy of Cancer|February 5, 2024
Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cellsGregory P Botta, Joseph Chao, Hong Ma, et al.
World Journal of Gastrointestinal Surgery|October 7, 2020
Impact of palliative therapies in metastatic esophageal cancer patients not receiving chemotherapySungjin Kim, Timothy P DiPeri, Michelle Guan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2025
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory <i>KRAS</i> G12C Colorectal CancerFilippo Pietrantonio, Lisa Salvatore, Taito Esaki, et al.
Annals of Surgical Oncology|August 13, 2021
PIPAC for the Treatment of Gynecologic and Gastrointestinal Peritoneal Metastases: Technical and Logistic Considerations of a Phase 1 TrialMustafa Raoof, Gautam Malhotra, Adrian Kohut, et al.
Pageof 12